Kelly Curtin

Kelly Curtin

Managing Director

London Office  |   |   +44 (0) 207 451 4564

Kelly Curtin, a Managing Director on Torreya’s European team, advises clients on strategic transactions across the life sciences industry. She has over 20 years of experience in investment banking, primarily in the healthcare industry.

Her experience includes strategic transactions across a wide spectrum of the life sciences, including biotechnology, pharma, specialty pharma, generics, healthcare services and medical devices. Kelly has led M&A transactions for public and private companies, licensing transactions and divestments as well as executed a range of equity and debt financings.

Recent transactions on which Kelly has worked include Orion’s global collaboration for the development and commercialization of ODM-208 with Merck, Medigene’s global multi-target collaboration with BioNTech to discover and develop TCR immunotherapies, Calliditas’ out-license of its specialty therapy for IgA Nephropathy in Europe to Stada, and the licensing of Mereo’s Navicixizumab to Oncologie.

Before joining Torreya in 2014, Kelly was a Director in Credit Suisse’s Mergers & Acquisitions group in Chicago and London.

Kelly holds a B.A. in Law, Jurisprudence and Social Thought from Amherst College.

Selected Transactions

Global collaboration for the development and commercialization of ODM-208 with
$290 million upfront
July 2022
Sale of U.S. manufacturing facility and long-term supply agreement with
$44.5 million
April 2022
Global multi-target collaboration to discover and develop TCR immunotherapies; acquisition of PRAME TCR
€26 million upfront
February 2022
Licensing of Budesolv in China to
October 2021
Out-license of specialty therapy for IgA Nephropathy in Europe to
Up to €97.5 million
plus royalties
July 2021
Recommended cash acquisition by
£48.3 million
November 2022
License of Galinpepimut-S in Greater China by
3D Medicines
Up to $202 million with $7.5 million upfront
December 2020
Mereo Biopharma
License of
Navicixizumab to
Up to $306 million
January 2020
Midatech Pharma PLC
Sale of Midatech Pharma US Inc. to Kanwa Holdings LP, an affiliate of Barings LLC
Up to $19 million
November 2018
Licensing of ex European rights for LYS-SAF302 to
Sarepta Therapeutics
Up to $125 Millionwith committed payments of $29m plus royalties
October 2018
Shield Therapeutics
Licensing agreement for Feraccru® in Europe, Australia and New Zealand with
£11 million upfront(plus up to £54.5m in milestones and 25-40% royalties)
September 2018
Midatech Pharma
Acquisition of
Dara Biosciences
Up to $30 million
December 2015